A spokesman for Novo said on Tuesday the company
aimed to get the case dismissed, but had no further comment.
In 2005 Caraco Pharmaceutical Laboratories, a subsidiary of Indian
drug maker Sun Pharmaceutical Industries, applied to get a generic
version of Prandin approved by 2009, when Novo's patent on the drug
In June 2005 Novo ﬁled a patent infringement lawsuit against Caraco,
which it lost last summer.
The purchasing companies — American Sales Co, Rochester Drug Co-op
and Cardinal — said the case wrongfully delayed generic competition
for Prandin and claim compensation for this, Danish daily
Jyllands-Posten reported, adding the size of the compensation claim
was not disclosed.
Novo has in recent years reaped U.S. sales of $200 million and $250
million per year from Prandin.
(Reporting by Shida Chayesteh and Teis
Jensen; editing by David Holmes)
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.